Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

NCT04714827 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: KQ-2003 CAR-T cells

Sponsor

Shanxi Province Cancer Hospital

Collaborators

[object Object]